Aligos Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-04-12
- Employees
- 66
- Market Cap
- -
- Website
- http://www.aligos.com
- Introduction
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
Clinical Trials
14
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
- Conditions
- Chronic Hepatitis B Infection
- Interventions
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 200
- Registration Number
- NCT06963710
A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT06959888
- Locations
- 🇺🇸
PPD Austin CRU, Austin, Texas, United States
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects with Renal Impairment and in Healthy Subjects with Normal Renal Function
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT06698549
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Genesis Clinical Trials, Tampa, Florida, United States
A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT06672900
- Locations
- 🇺🇸
PPD Austin Research Unit, Austin, Texas, United States
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects with Hepatic Impairment and in Healthy Subjects with Normal Hepatic Function
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 16
- Registration Number
- NCT06568861
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
- Prev
- 1
- 2
- 3
- Next
News
Aligos Therapeutics Strengthens CMC Leadership with Industry Veteran Ahead of Phase 2 Trial
Aligos Therapeutics has appointed Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls (CMC), bringing over 20 years of pharmaceutical development experience to the company.
FDA Approves Tablet Formulation of LIVMARLI for Rare Pediatric Liver Diseases
Mirum Pharmaceuticals' LIVMARLI (maralixibat) has received FDA approval for a new tablet formulation to treat cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis.
Aligos Therapeutics Reports Promising 96-Week Data for HBV Treatment and Positive Results in MASH Study at APASL 2025
Aligos Therapeutics presented 96-week data showing ALG-000184 achieved significant HBV DNA suppression in both HBeAg-positive and HBeAg-negative patients, positioning it as a potential first-line therapy for chronic hepatitis B.
Aligos Therapeutics Secures $105M Financing to Advance Hepatitis B Drug Development
• Aligos Therapeutics has secured a $105 million private placement financing led by a life sciences investment firm, strengthening its position to advance ALG-000184 into Phase 2 clinical trials for chronic hepatitis B. • The financing structure includes a combination of common stock shares and warrants, with the transaction expected to close by February 13, 2025. • The funding is projected to extend Aligos' cash runway into the second half of 2026, supporting the company's continued development of liver and viral disease therapeutics.
Aligos Therapeutics' ALG-000184 Receives FDA IND Clearance for Hepatitis B
• Aligos Therapeutics received FDA clearance for its Investigational New Drug (IND) application for ALG-000184, a capsid assembly modulator for chronic hepatitis B (CHB). • A Phase 1 Drug-Drug Interaction (DDI) study will assess the impact of cytochrome P450 inhibitors and inducers on ALG-000184 pharmacokinetics. • Phase 2 enabling activities are underway, with a Phase 2 study filing anticipated in Q1 2025, evaluating ALG-000184 against standard of care in CHB subjects. • ALG-000184 has demonstrated broad antiviral activity, potentially improving outcomes compared to current treatments for chronic hepatitis B.
Aligos Therapeutics' ALG-055009 Shows Promise in Phase IIa MASH Trial
• Aligos Therapeutics announced positive results from its Phase IIa HERALD trial of ALG-055009 for MASH, demonstrating notable liver fat reduction. • The trial, involving 102 subjects, showed that doses of ALG-055009 led to up to 70% of subjects experiencing a ≥30% relative decrease in liver fat. • ALG-055009 exhibited a favorable tolerability profile with mainly mild to moderate adverse events and significant decreases in atherogenic lipids. • Aligos is currently evaluating options to fund continued development, with plans to complete activities for a Phase IIb study by mid-2025.